NLRP3 and acute kidney injury: With favorable oral bioavailability and an established safety profile in Phase II trials, Dapansutrile presents as a viable therapeutic candidate for clinical translation, particularly for NLRP3-driven conditions such as AKI and chronic inflammatory diseases where treatment options remain limited.